Investment Landscape: Parkinson's Disease covers the current R&D investment, [@clinicaltrialsgov] clinical trial pipeline, and funding trends for Parkinson's Disease research.
Last updated: 2026-03-17 19:20 PT
Clinical Trial Pipeline
Total Clinical Trials: 4613
Active Trials (Recruiting/Active): 1061
Parkinson's disease has 4,613 total clinical trials with 1,061 currently active. The Phase 3 portfolio (253 trials) is substantially smaller than Phase 2 (485), indicating a bottleneck in late-stage clinical development. This gap represents a critical investment opportunity.
Key Investment Themes
...
Investment Landscape: Parkinson's Disease
Overview
Investment Landscape: Parkinson's Disease covers the current R&D investment, [@clinicaltrialsgov] clinical trial pipeline, and funding trends for Parkinson's Disease research.
Last updated: 2026-03-17 19:20 PT
Clinical Trial Pipeline
Total Clinical Trials: 4613
Active Trials (Recruiting/Active): 1061
Parkinson's disease has 4,613 total clinical trials with 1,061 currently active. The Phase 3 portfolio (253 trials) is substantially smaller than Phase 2 (485), indicating a bottleneck in late-stage clinical development. This gap represents a critical investment opportunity.
Key Investment Themes
Alpha-Synuclein Targeting: Major focus on oligomerization and aggregation inhibitors
Neuroprotection: Strong pipeline for disease-modifying therapies
Levodopa Optimization: Continued investment in motor symptom management
Non-Motor Symptoms: Growing attention to cognitive, autonomic, and sleep manifestations
Emerging Investment Areas
The high number of terminated trials (250) highlights the need for novel approaches. LRRK2 inhibitors remain a major focus given the genetic link to sporadic PD. [GBA](/entities/gba)-targeted therapies are emerging for the significant subset of patients with GBA mutations. Inflammatory modulation targeting [NLRP3](/entities/nlrp3-inflammasome) and other inflammasome components represents a promising new frontier.
Priority Research Gaps
Late-Stage Development Bottleneck
Only 5.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Recommended Priorities
Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints
Trial Design Innovation: Adaptive trials and platform protocols
Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure
Therapeutic Target Priorities
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
mitochondrial: 433 trials - Well-established
genetic: 209 trials - Well-established
neurotransmitter: 164 trials - Well-established
amyloid: 160 trials - Well-established
alpha-synuclein: 81 trials - Well-established
Recent Investment Developments (2024-2025)
Key Pipeline Updates (2025)
BIIB122 (Denali/Biogen): LRRK2 inhibitor showing promise in Phase 2b LUMA study, potential for disease modification
Cinpanemab (Prothelia): Alpha-synuclein antibody in Phase 2, targets spreading of pathology
ATP10B (PTC Therapeutics): Gene therapy for GBA-carrier PD advancing to Phase 2
Vyalto (AbbVie): AAV-based gene therapy for AADC deficiency approved, broader PD applications in development
Genetic subtypes: LRRK2 and GBA carriers represent distinct therapeutic targets with dedicated programs
Alpha-synuclein targeting: Antibodies, ASOs, and small molecule aggregation inhibitors in development
Neuroinflammation: NLRP3 inhibitors, TREM2 modulators in early trials
DBS and device therapy: Investment in closed-loop neurostimulation systems
Recent Deals
AbbVie/Cerevel ($8.7B): Acquired tavaborole (Kaindi) and early PD pipeline
Roche/Prothelia: Expanded partnership for alpha-synuclein programs
Novo Nordisk/P.A.N.: GLP-1 agonist trials in PD showing motor symptom benefits
Investment Outlook
Near-Term Opportunities (1-3 Years)
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Medium-Term Opportunities (3-5 Years)
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Long-Term Vision (5-10 Years)
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.